



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



sPLA₂ (Type X) Inhibitor Screening Assay Kit

Item No. 702480

www.caymanchem.com

Customer Service 800.364.9897

Technical Support 888.526.5351

1180 E. Ellsworth Rd · Ann Arbor, MI · USA

TABLE OF CONTENTS

GENERAL INFORMATION	3	Materials Supplied
	4	Safety Data
	4	Precautions
	4	If You Have Problems
	4	Storage and Stability
	5	Materials Needed but Not Supplied
INTRODUCTION	6	Background
	7	About This Assay
PRE-ASSAY PREPARATION	8	Sample Preparation
	8	Reagent Preparation
ASSAY PROTOCOL	10	Plate Set Up
	12	Performing the Assay
ANALYSIS	13	Calculations
	14	Performance Characteristics
RESOURCES	19	Troubleshooting
	20	Assay Reagent Preparation Summary
	21	Assay Summary
	22	References
	23	Notes
	23	Warranty and Limitation of Remedy

GENERAL INFORMATION

Materials Supplied

Kit will arrive packaged as a -80°C kit. After opening kit, store individual components as stated below.

Item Number	Item	Quantity/Size	Storage
400587	sPLA ₂ Assay Buffer (5X)	1 vial/12 ml	-20°C
400588	sPLA ₂ (Type X) Substrate Resuspension Buffer	1 vial/8 ml	-20°C
400589	sPLA ₂ (Type X) Substrate	1 vial/550 µl	-20°C
400590	sPLA ₂ Assay Probe	1 vial/6 ml	-20°C
400591	sPLA ₂ (Type X) Enzyme (human, recombinant)	1 vial/200 µl	-80°C
400592	sPLA ₂ Control Inhibitor	1 vial/220 µl	-20°C
400593	384-Well Clear Bottom Black Plate	1 plate	RT

If any of the items listed above are damaged or missing, please contact our Customer Service department at (800) 364-9897 or (734) 971-3335. We cannot accept any returns without prior authorization.



WARNING: THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Safety Data

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

Precautions

Please read these instructions carefully before beginning this assay.

This kit may not perform as described if any reagent or procedure is replaced or modified.

If You Have Problems

Technical Service Contact Information

Phone: 888-526-5351 (USA and Canada only) or 734-975-3888

Email: techserv@caymanchem.com

In order for our staff to assist you quickly and efficiently, please be ready to supply the lot number of the kit (found on the outside of the box).

Storage and Stability

This kit will perform as specified if stored as directed in the **Materials Supplied** section (see page 3) and used before the expiration date indicated on the outside of the box.

Materials Needed But Not Supplied

1. A plate reader with the ability to measure absorbance at a wavelength of 410 nm
2. Adjustable pipettes; multichannel or repeating pipettor recommended
3. An orbital microplate shaker
4. A source of pure water; glass-distilled water or deionized water is acceptable
NOTE: UltraPure Water is available for purchase from Cayman (Item No. 400000)
5. Aluminum foil
6. DMSO

Background

Secretory phospholipase A₂ (sPLA₂) (Type X) is a calcium-dependent PLA₂ superfamily member that is encoded by *PLA2G10* in humans.¹ It is expressed in the spleen, thymus, pancreas, lung, and colon, as well as peripheral blood leukocytes, neutrophils, and keratinocytes.²⁻⁴ Upon activation, sPLA₂ (Type X) is released into the extracellular space where it acts in a paracrine or autocrine manner and preferentially catalyzes the hydrolysis of phosphatidylethanolamine (PE) and phosphatidylcholine (PC) over phosphatidylserine (PS) at the *sn*-2 position, liberating the free fatty acid and lysophospholipid, which serve as substrates for the synthesis of bioactive lipid metabolites.^{1,2} sPLA₂ (Type X) hydrolyzes lymphoma-derived extracellular vesicles (EVs), changing their size and morphology resulting in increased uptake by macrophages and increases the levels of EV-secreted lipid mediators.⁵ Inhibition of sPLA₂ (Type X) reduces lymphoma growth in a mouse model of Epstein-Barr virus-induced B cell lymphoma, and sPLA₂ (Type X) levels in macrophages are negatively correlated with survival in patients with diffuse large B cell lymphoma (DLBCL). In addition, serum exosomal sPLA₂ (Type X) protein levels are increased in patients with non-small cell lung cancer (NSCLC).⁶ sPLA₂ (Type X) levels are increased in sputum, as well as bronchial macrophages and columnar epithelial cells, in patients with asthma.⁷ Based on these data, sPLA₂ (Type X) is a potential diagnostic and prognostic biomarker of NSCLC, and inhibition of sPLA₂ (Type X) is a potential therapeutic strategy in cancer and asthma.

About This Assay

Cayman's sPLA₂ (Type X) Inhibitor Screening Assay Kit provides a robust and easy-to-use platform for identifying novel inhibitors of human sPLA₂ (Type X), a phospholipase that hydrolyzes PE and PC at the *sn*-2 position. The assay uses a sulfur-containing analog of 1,2-diheptanoyl-*sn*-glycero-3-PC (di-C7-PC) as a substrate. Upon hydrolysis by sPLA₂ (Type X) at the *sn*-2 position, free thiols can be detected by the sPLA₂ Assay Probe resulting in a product that can be easily quantified using its absorbance at a wavelength of 410 nm. The potent and reversible sPLA₂ (Type X) inhibitor, sPLA₂ Control Inhibitor, also known as LY315920 or varespladib, is included as a positive control and inhibits the enzyme with an IC₅₀ value of approximately 11 nM.

Sample Preparation

All inhibitors, be they small molecules, natural products, or proteins, should be prepared in a suitable solvent such as sPLA₂ Assay Buffer (1X), DMSO, dimethyl formamide (DMF), or short-chain alcohols (e.g., MeOH, EtOH) at a concentration 35X the desired final assay concentration (e.g., for 10 μM final assay concentration, a 350 μM stock should be made). The final concentration of the inhibitor diluent in the assay is 2.9% (see **Effects of Solvents** on page 17).

Reagent Preparation

1. sPLA₂ Assay Buffer (5X) - (Item No. 400587)

Mix 10 ml of sPLA₂ Assay Buffer (5X) with 40 ml of pure water to make 50 ml of sPLA₂ Assay Buffer (1X). Once prepared, the sPLA₂ Assay Buffer (1X) may be stored at 4°C for at least three months.

2. sPLA₂ (Type X) Substrate Resuspension Buffer - (Item No. 400588)

This vial contains 8 ml of sPLA₂ (Type X) Substrate Resuspension Buffer. Once thawed, it is ready to use as supplied. If all of the sPLA₂ (Type X) Substrate Resuspension Buffer will not be used at one time, aliquot and store it at -20°C.

3. sPLA₂ (Type X) Substrate - (Item No. 400589)

This vial contains 13.75 mg of sPLA₂ (Type X) Substrate in 550 μl of ethanol (25 mg/ml concentration). For a full plate, completely evaporate all of the solvent under a gentle stream of inert gas (e.g. nitrogen, argon). The substrate will appear as a clear solid. Resuspend the substrate in 4.7 ml of sPLA₂ (Type X) Substrate Resuspension Buffer for a final concentration of 2.93 mg/ml.

For a half a plate, aliquot 225 μl of substrate in solution, evaporate off the solvent, and resuspend in 2.35 ml of sPLA₂ (Type X) Resuspension Buffer. Unused substrate should be stored as an ethanol solution at -20°C, where it will be stable for at least six months. Resuspended substrate in sPLA₂ (Type X) Substrate Resuspension Buffer will be stable at room temperature for up to four hours, and at least two weeks at -20°C.

4. sPLA₂ Assay Probe - (Item No. 400590)

This vial contains 6 ml of sPLA₂ Assay Probe. Mix 5 ml of sPLA₂ Assay Probe with 14 ml of sPLA₂ Assay Buffer (1X). Keep the diluted probe on ice until use. The diluted sPLA₂ Assay Probe will be stable for up to four hours on ice. It can be stored at -20°C for up to 3 months, limiting freeze-thaw cycles.

5. sPLA₂ (Type X) Enzyme (human, recombinant) - (Item No. 400591)

sPLA₂ (Type X) Enzyme (human, recombinant) should be thawed on ice and gently mixed prior to dilution. To dilute the enzyme, mix 150 μl of sPLA₂ (Type X) Enzyme (human, recombinant) with 8.85 ml sPLA₂ Assay Buffer (1X). It is recommended that the enzyme be diluted immediately prior to performing the assay. The diluted enzyme loses 50% of its activity in one hour when stored on ice. The undiluted enzyme can be stored at -80°C, limiting freeze-thaw cycles.

6. sPLA₂ Control Inhibitor - (Item No. 400592)

This vial contains 200 μl of 1 mM sPLA₂ Control Inhibitor in DMSO, which can be used as a positive control. Mix 10 μl of sPLA₂ Control Inhibitor with 90 μl DMSO to make a 100 μM working solution. If all of the sPLA₂ Control Inhibitor will not be used at one time, aliquot the undiluted inhibitor and store at -20°C.

ASSAY PROTOCOL

Plate Set Up

The 384-well plate(s) included with this kit is supplied ready to use. There is no specific pattern for using the wells on the plate. However, it is necessary to have three wells designated as 100% initial activity and three wells designated as background. It is suggested that each inhibitor, including the positive control sPLA₂ Control Inhibitor, be assayed at least in triplicate (quadruplicate preferred). A typical layout of samples to be measured in triplicate is shown in Figure 1, below.

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
A	A	A	A	14	14	14	30	30	30	46	46	46	62	62	62	78	78	78	94	94	94	110	110	110
B	BW	BW	BW	15	15	15	31	31	31	47	47	47	63	63	63	79	79	79	95	95	95	111	111	111
C	PC	PC	PC	16	16	16	32	32	32	48	48	48	64	64	64	80	80	80	96	96	96	112	112	112
D	1	1	1	17	17	17	33	33	33	49	49	49	65	65	65	81	81	81	97	97	97	113	113	113
E	2	2	2	18	18	18	34	34	34	50	50	50	66	66	66	82	82	82	98	98	98	114	114	114
F	3	3	3	19	19	19	35	35	35	51	51	51	67	67	67	83	83	83	99	99	99	115	115	115
G	4	4	4	20	20	20	36	36	36	52	52	52	68	68	68	84	84	84	100	100	100	116	116	116
H	5	5	5	21	21	21	37	37	37	53	53	53	69	69	69	85	85	85	101	101	101	117	117	117
I	6	6	6	22	22	22	38	38	38	54	54	54	70	70	70	86	86	86	102	102	102	118	118	118
J	7	7	7	23	23	23	39	39	39	55	55	55	71	71	71	87	87	87	103	103	103	119	119	119
K	8	8	8	24	24	24	40	40	40	56	56	56	72	72	72	88	88	88	104	104	104	120	120	120
L	9	9	9	25	25	25	41	41	41	57	57	57	73	73	73	89	89	89	105	105	105	121	121	121
M	10	10	10	26	26	26	42	42	42	58	58	58	74	74	74	90	90	90	106	106	106	122	122	122
N	11	11	11	27	27	27	43	43	43	59	59	59	75	75	75	91	91	91	107	107	107	123	123	123
O	12	12	12	28	28	28	44	44	44	60	60	60	76	76	76	92	92	92	108	108	108	124	124	124
P	13	13	13	29	29	29	45	45	45	61	61	61	77	77	77	93	93	93	109	109	109	125	125	125

A = 100% Initial Activity Wells
 BW = Background Wells
 PC = Positive Control Wells
 1-125 = Sample Wells

Figure 1. Sample plate format

Pipetting Hints

- It is recommended that a multichannel pipette be used to deliver reagents to the wells. This saves time and helps maintain more precise incubation times.
- Before pipetting each reagent, equilibrate the pipette tip in that reagent (i.e., slowly fill the tip and gently expel the contents, repeat several times).
- Do not expose the pipette tip to the reagent(s) already in the well.

General Information

- The final volume of the assay is 70 µl in all the wells.
- All reagents should be prepared as described above. The sPLA₂ (Type X) enzyme should be kept on ice and all other reagents should be kept at room temperature before beginning the assay.
- It is not necessary to use all the wells on the plate at one time.
- It is recommended to assay the samples in triplicate (quadruplicate is preferred) but it is at the user's discretion to do so.
- The assay is performed at room temperature.
- Measure the absorbance at a wavelength of 410 nm.

Performing the Assay

1. **Background Wells:** add 38 μl of the diluted sPLA₂ Assay Probe, 20 μl of sPLA₂ Assay Buffer (1X), and 2 μl of solvent to three wells. Use the same solvent used for the unknown inhibitor and the positive control, sPLA₂ Control Inhibitor. If different solvents are to be assayed at the same time, separate sets of background wells should be run for each solvent.
2. **100% Initial Activity Wells:** add 38 μl of the diluted sPLA₂ Assay Probe, 20 μl of the diluted sPLA₂ (Type X) Enzyme, and 2 μl of solvent to three wells. Use the same solvent used for the unknown inhibitor and the positive control, sPLA₂ Control Inhibitor. If inhibitors in different solvents are to be assayed at the same time, separate sets of 100% initial activity wells should be set up for each solvent.
3. **Inhibitor/Positive Control Wells:** add 38 μl of the diluted sPLA₂ Assay Probe, 20 μl of the diluted sPLA₂ (Type X) Enzyme, and 2 μl of unknown inhibitor or the 100 μM positive control, sPLA₂ Control Inhibitor working solution, to three wells.
4. Incubate for 15 minutes at room temperature.
5. Initiate the reactions by adding 10 μl of reconstituted sPLA₂ (Type X) Substrate to all the wells being used. Mix on an orbital microplate shaker for one minute.
6. Cover the plate with foil and incubate for 60 minutes at room temperature.
7. Remove the foil and read the absorbance at a wavelength of 410 nm.

NOTE: If desired, the assay may be read kinetically rather than as an endpoint. If reading kinetically, skip step #6 above. The absorbance should be measured at least once per minute at room temperature for 60 minutes. Determine the initial rate based on the linear portion of the kinetic curve. Calculations can be performed as shown below substituting initial rates for average absorbance.

ANALYSIS

Calculations

1. Determine the average absorbance of each sample.
2. Subtract the average absorbance of the background wells from the average absorbance of the 100% initial activity and inhibitor wells. These are the corrected values.
3. Determine the percent inhibition or percent activity for each inhibitor using one of the following equations:

$$\% \text{ inhibition} = \left[\frac{\text{corrected 100\% initial activity} - \text{corrected inhibitor activity}}{\text{corrected 100\% initial activity}} \right] \times 100$$

$$\% \text{ activity} = \left[\frac{\text{corrected inhibitor activity}}{\text{corrected 100\% initial activity}} \right] \times 100$$

4. Graph the percent inhibition or percent activity as a function of inhibitor concentration to determine the IC₅₀ value (the concentration at which there is 50% inhibition) of the inhibitor. Inhibition of recombinant human sPLA₂ (Type X) by sPLA₂ Control Inhibitor is shown in Figure 2 (see page 15).

Performance Characteristics

Z' Factor:

Z' factor is a term used to describe the robustness of an assay, which is calculated using the equation below.⁸

$$Z' = 1 - \frac{3\sigma_{c+} + 3\sigma_{c-}}{|\mu_{c+} - \mu_{c-}|}$$

Where σ : Standard deviation
 μ : Mean
c+: Positive control
c-: Negative control

The theoretical upper limit for the Z' factor is 1.0. A robust assay has a Z' factor >0.5. The Z' factor for Cayman's sPLA₂ (Type X) Inhibitor Screening Assay Kit was determined to be 0.91.

Sample Data:




Figure 2. Inhibition of recombinant human sPLA₂ (Type X) by sPLA₂ Control Inhibitor. Data are plotted as the mean of triplicate measurements \pm the standard deviation. The vehicle control (Veh.) represents 100% initial activity. The IC₅₀ value of sPLA₂ Control Inhibitor is 11 nM.




Figure 3. Typical performance data for the sPLA₂ (Type X) Inhibitor Screening Assay Kit. Data are shown from 32 replicates each for 100% initial activity wells and 2.9 μM sPLA₂ Control Inhibitor prepared as described in the kit booklet. The calculated Z' factor for this experiment was 0.91. The red lines correspond to three standard deviations from the mean for each control value.

Effects of Solvents:

Compounds may be prepared in organic solvents such as DMSO, DMF, or short-chain alcohols (e.g., MeOH, EtOH). The final concentration of the inhibitor diluent in the assay is 2.9%. A titration of organic solvents showed that signal can change with increasing solvent concentration, so the proper vehicle control should be included in the assay.




Figure 4. The effect of solvent on the readout of sPLA₂ (Type X) activity. The data are shown as the mean ± standard deviation for quadruplicate reactions containing the indicated concentration of solvents. The dotted line represents sPLA₂ (Type X) activity in sPLA₂ Assay Buffer (1X).

Precision:

Intra-assay precision was determined by analyzing 15 measurements of the background, 100% initial activity, and 2.9 μM sPLA₂ Control Inhibitor on the same day. The intra-assay coefficients of variation were 7, 7, and 2%, respectively. The intra-assay coefficient of variation for the IC₅₀ value of 15 inhibition curves performed on the same day was 15%.

Inter-assay precision was determined by analyzing inhibition with sPLA₂ Control Inhibitor in six separate assays on three different days. The inter-assay coefficient of variance for the IC₅₀ value was 14%.

RESOURCES

Troubleshooting

Problem	Possible Causes	Recommended Solutions
Erratic values; dispersion of triplicates/quadruplicates	A. Poor pipetting/technique B. Bubble in the well(s)	A. Be careful not to splash the contents of the wells B. Carefully tap the side of the plate with your finger to remove bubbles
No absorbance above background is seen in the Inhibitor wells	A. Enzyme, probe, or substrate was not added to the well(s) or the enzyme has degraded. B. Inhibitor concentration is too high and inhibited all of the enzyme activity	A. Make sure to add all components to the wells. Use the diluted enzyme immediately or store it on ice for not more than 1 hour. B. Reduce the concentration of the inhibitor and re-assay
No inhibition seen with inhibitor	A. The inhibitor concentration is not high enough B. The compound is not an inhibitor of the enzyme	Increase the inhibitor concentration and re-assay

Reagent	Procedure
sPLA ₂ Assay Buffer (5X)	Dilute 1:5 with pure water to make Assay Buffer (1X)
sPLA ₂ (Type X) Substrate Resuspension Buffer	Ready to use as supplied
sPLA ₂ (Type X) Substrate	<ol style="list-style-type: none"> Evaporate ethanol under a gentle stream of inert gas Resuspend the substrate in 4.7 ml of sPLA₂ (Type X) Substrate Resuspension Buffer or resuspend the amount needed to a final concentration of 2.93 mg/ml
sPLA ₂ Assay Probe	Dilute 5 ml of sPLA ₂ Assay Probe with 14 ml of sPLA ₂ Assay Buffer (1X)
sPLA ₂ (Type X) Enzyme	Dilute 1:60 with sPLA ₂ Assay Buffer (1X)
sPLA ₂ Control Inhibitor	Dilute to 1:10 with DMSO to make a 100 μM inhibitor working solution

Table 1. Assay reagent preparation summary

Procedure	Background Wells	100% Activity Wells	Positive Control Wells	Inhibitor Wells
Add diluted sPLA ₂ Assay Probe	38 μl	38 μl	38 μl	38 μl
Add sPLA ₂ Assay Buffer (1X)	20 μl	--	--	--
Add diluted sPLA ₂ (Type X) Enzyme	--	20 μl	20 μl	20 μl
Add solvent	2 μl	2 μl	--	--
Add 100 μM sPLA ₂ Control Inhibitor	--	--	2 μl	--
Add Test Inhibitor (35X)	--	--	--	2 μl
Incubate	Incubate for 15 minutes at room temperature.			
Add reconstituted sPLA ₂ (Type X) Substrate	10 μl	10 μl	10 μl	10 μl
Mix, Incubate, and Read	Mix on an orbital microplate shaker for 1 minute. Cover with foil and incubate at room temperature for 60 minutes. Read absorbance at 410 nm.			

Table 2. Assay summary

References

1. Murakami, M., Taketomi, Y., Sato, H., *et al.* Secreted phospholipase A₂ revisited. *J. Biochem.* **150(3)**, 233-255 (2011).
2. Cupillard, L., Koumanov, K., Mattéi, M.G., *et al.* Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A₂. *J. Biol. Chem.* **272(25)**, 15745-15752 (1997).
3. Degousee, N., Ghomashchi, F., Stefanski, E., *et al.* Groups IV, V, and X phospholipases A₂s in human neutrophils. Role in eicosanoid production and Gram-negative bacterial phospholipid hydrolysis. *J. Biol. Chem.* **277(7)**, 5061-5073 (2002).
4. Schadow, A., Scholz-Pedretti, K., Lambeau, G., *et al.* Characterization of group X phospholipase A₂ as the major enzyme secreted by human keratinocytes and its regulation by the phorbol ester TPA. *J. Invest. Dermatol.* **116(1)**, 31-39 (2001).
5. Kudo, K., Miki, Y., Carreras, J., *et al.* Secreted phospholipase A₂ modifies extracellular vesicles and accelerates B cell lymphoma. *Cell Metab.* **34(4)**, 615-633 (2022).
6. Chen, Y., Ma, X., Lou, C., *et al.* PLA2G10 incorporated in exosomes could be diagnostic and prognostic biomarker for non-small cell lung cancer. *Clin. Chim. Acta* **530**, 55-65 (2022).
7. Hallstrand, T.S., Chi, E.Y., Singer, A.G., *et al.* Secreted phospholipase A₂ group X overexpression in asthma and bronchial hyperresponsiveness. *Am. J. Respir. Crit. Care Med.* **176(11)**, 1072-1078 (2007).
8. Zhang, J.-H., Chung, T.D.Y., and Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J. Biomol. Screen.* **4(2)**, 67-73 (1999).

NOTES

Warranty and Limitation of Remedy

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

This document is copyrighted. All rights are reserved. This document may not, in whole or part, be copied, photocopied, reproduced, translated, or reduced to any electronic medium or machine-readable form without prior consent, in writing, from Cayman Chemical Company.

©08/07/2023, Cayman Chemical Company, Ann Arbor, MI, All rights reserved.
Printed in U.S.A.

